Julio Sánchez de Cos Escuín1, José Abal Arca2, Rosario Melchor Íñiguez3, Luis Miravet Sorribes4, Ana Núñez Ares5, Jesús R Hernández Hernández6, Luis García Arangüena7, Manuel Núñez Delgado8, Ma José Pavón Fernández9, Gloria Francisco Corral10, Leonardo de Esteban Júlvez11, Ma Teresa González Budiño12, Francisco Abad Cavaco13, Emilio Ansótegui Barrera13, Felipe Andreo García14, Mireia Serra Mitjans15, Helena Hernández Rodríguez16. 1. Pulmonology Section, Hospital San Pedro de Alcántara, Cáceres, Spain; Biomedical Research Center Network for Respiratory Diseases (CibeRes), Spain. Electronic address: juli1949@separ.es. 2. Pulmonology Section, Complejo Hospitalario de Ourense, Spain. 3. Pulmonology Section, Fundación Jiménez Díaz, Madrid, Spain. 4. Pulmonology Section, Hospital de La Plana, Castelló, Spain. 5. Pulmonology Section, Complejo Hospitalario de Albacete, Spain. 6. Pulmonology Section, Hospital Nª Sª de Sonsoles, Ávila, Spain. 7. Pulmonology Section, Hospital de Sierrallana, Torrelavega, Cantabria, Spain. 8. Pulmonology Section, Hospital de Meixoeiro, Vigo, Spain. 9. Pulmonology Section, Hospital de Leganés, Madrid, Spain. 10. Pulmonology Section, Complejo Hospitalario La Mancha Centro, Ciudad Real, Spain. 11. Pulmonology Section, Hospital Joan XXIII, Tarragona, Spain. 12. Pulmonology Section, Hospital Central de Asturias, Oviedo, Spain. 13. Pulmonology Section, Hospital La Fe, Valencia, Spain. 14. Pulmonology Section, Hospital Germans Trias i Pujol, Barcelona, Spain. 15. Thoracic Surgery, Hospital Universitari Mutua Terrassa, Spain. 16. Thoracic Surgery, Hospital Universitario de Tenerife, Spain.
Abstract
INTRODUCTION: The current edition of the tumor, node and metastasis (TNM) classification of lung cancer (LC) divides the presence of metastasis (M1) into two categories: M1a and M1b, depending on its anatomical location. To assess this new classification, the survival and the M descriptors of LC patients with metastatic disease registered by the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery II (GCCB-S-II), were analyzed. METHODS: Non-small cell lung cancer (NSCLC) patients, with M1a or M1b disease, included in the GCCB-S-II, from April 2009 to December 2010, staged in accordance with the prospective staging project protocol of the International Association for the Study of Lung Cancer (IASLC), and with complete TNM staging and follow-up data, were studied. The overall survival associated with each M1 category and each M descriptor, besides other prognostic factors (sex, age, performance status [PS] and others) were analyzed by univariate and multivariate models. RESULTS: 640 NSCLC patients (195 M1a and 445 M1b) were included. M1b tumors had significantly worse survival than M1a tumors (p < 0.001). The prognostic value of M1 category was independent from other prognostic variables such as PS, weight loss, and others. The number of metastatic sites (isolated versus multiple) and the number of lesions (single versus multiple) in patients with isolated metastasis showed prognostic value, especially in those with brain metastasis. CONCLUSION: The current division of the M1 category into two subsets (M1a and M1b) is warranted by their prognostic significance. The number of metastatic sites and the number of lesions in patients with isolated metastasis should be taken into account, because they also have prognostic relevance.
INTRODUCTION: The current edition of the tumor, node and metastasis (TNM) classification of lung cancer (LC) divides the presence of metastasis (M1) into two categories: M1a and M1b, depending on its anatomical location. To assess this new classification, the survival and the M descriptors of LC patients with metastatic disease registered by the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery II (GCCB-S-II), were analyzed. METHODS:Non-small cell lung cancer (NSCLC) patients, with M1a or M1b disease, included in the GCCB-S-II, from April 2009 to December 2010, staged in accordance with the prospective staging project protocol of the International Association for the Study of Lung Cancer (IASLC), and with complete TNM staging and follow-up data, were studied. The overall survival associated with each M1 category and each M descriptor, besides other prognostic factors (sex, age, performance status [PS] and others) were analyzed by univariate and multivariate models. RESULTS: 640 NSCLCpatients (195 M1a and 445 M1b) were included. M1b tumors had significantly worse survival than M1a tumors (p < 0.001). The prognostic value of M1 category was independent from other prognostic variables such as PS, weight loss, and others. The number of metastatic sites (isolated versus multiple) and the number of lesions (single versus multiple) in patients with isolated metastasis showed prognostic value, especially in those with brain metastasis. CONCLUSION: The current division of the M1 category into two subsets (M1a and M1b) is warranted by their prognostic significance. The number of metastatic sites and the number of lesions in patients with isolated metastasis should be taken into account, because they also have prognostic relevance.
Authors: Sergio Nicola Forti Parri; Barbara Bonfanti; Alessandra Cancellieri; Dario De Biase; Rocco Trisolini; Stefania Zoboli; Luca Bertolaccini; Piergiorgio Solli; Giovanni Tallini Journal: Ann Transl Med Date: 2017-10